With growth signals mixed across major economies, inflation trends diverging by region and central banks moving at different speeds, investors are paying closer attention to what really sits behind a stock: its cash generation. The Undervalued Stocks Based On Cash Flows screener focuses on companies where SWS DCF valuation suggests their future cash flows may not be fully reflected in the current share price. That combination of cash flow potential and discounted pricing can be especially interesting when market sentiment is swinging between risk-on and risk-off. This article highlights three stocks from the screener that illustrate how this theme works in practice.

Kyndryl Holdings (KD)

Overview: Kyndryl Holdings is a global IT services company that designs, runs, and manages large-scale technology infrastructure, helping enterprises move to cloud, use data and AI more effectively, secure their systems, and modernize legacy platforms across industries like finance, healthcare, government, and telecom.

Operations: Kyndryl generates about US$2.3b of revenue in Japan, US$3.8b in the United States, US$5.4b from Principal Markets, and US$3.6b from Strategic Markets, reflecting a broad, globally diversified customer base.

Market Cap: US$2.4b

Kyndryl Holdings catches the eye because its cash flow potential and valuation signals are pulling in a different direction from its recent share price weakness. The company is leaning into cloud, AI, and cybersecurity partnerships with AWS, Google Cloud, and Microsoft, supported by contract wins such as US state DMV modernizations and recognition for outsourced digital workplace services. At the same time, high debt, thin current margins and dependence on replacing older, lower margin contracts keep execution risk high. For investors who want to understand whether these AI and cloud partnerships can outweigh the funding and legacy-contract pressures, there is more to unpack in the full Kyndryl story.

Cloud and AI partnerships at Kyndryl appear to be starting to offset the legacy drag, but the real tension lies in how funding and contract quality are reflected in the 4 key rewards and 1 important warning sign

T1 Energy (TE)

Overview: T1 Energy is an Austin based company that provides energy solutions for solar modules and cells, manufacturing and selling photovoltaic solar modules for customers in the United States, Norway, and other international markets.

Operations: T1 Energy currently generates around US$879.5m in revenue from the development of lithium ion batteries.

Market Cap: US$2.6b

T1 Energy draws interest because it sits at the intersection of rising electricity demand, U.S. policy support for clean energy, and a push for domestic supply chains. At the same time, it is still working through losses and a short cash runway. The company is scaling large U.S. solar manufacturing facilities, pursuing battery storage through the planned KORE Power acquisition, and securing long term utility contracts that could make future cash flows more predictable. However, dependence on tax credits, heavy capital needs, and recent dilution mean funding risk and governance quality matter a lot. For investors who want to see how this mix of policy tailwinds, capacity growth, and balance sheet pressure plays into T1 Energy’s valuation and cash flow profile, there is much more beneath the surface.

Rising U.S. clean energy support and T1 Energy’s push into large scale solar and storage make its funding puzzle even more important, so the T1 Energy financial health report could be the missing twist in the story

AbbVie (ABBV)

Overview: AbbVie is a global biopharmaceutical company that develops and sells medicines for autoimmune and inflammatory diseases, blood cancers, neurological and psychiatric conditions, eye disorders, viral infections, and aesthetics, with well known products such as Skyrizi, Rinvoq, Vraylar, Botox, and migraine therapies like Qulipta and Ubrelvy.

Operations: AbbVie generates about US$62.8b in revenue from its innovative medicines and therapies segment, with around US$47.6b coming from the United States.

Market Cap: US$414.8b

AbbVie catches attention because its cash flow potential from growing immunology and neuroscience franchises sits beside concerns about high debt, negative equity, and a P/E that looks stretched versus biotech peers. Skyrizi, Rinvoq and the planned Apogee Therapeutics acquisition point to a deeper immunology pipeline. Dividend continuity, strong free cash flow and a Simply Wall St DCF value well above the current price suggest investors may be paying less for those future cash flows than they might expect. At the same time, earnings recently declined, a large one off loss distorts results, and the balance sheet is heavily geared. The key question is how this mix of pipeline expansion, forecast earnings growth and financial risk fits within AbbVie’s cash flow based valuation story.

AbbVie’s cash rich pipeline and premium P/E spark the real question: is the market misreading where the story goes next, or just underpricing the balance sheet risk hiding in the 2 key rewards and 4 important warning signs

The three stocks in this article are just a starting point, as the full Undervalued Stocks Based On Cash Flows screener has identified 126 more companies with cash flow stories and pricing gaps that could be just as compelling as these examples, all grouped inside the Undervalued Stocks Based On Cash Flows screener. Use Simply Wall St to identify and analyze the specific catalysts, balance sheet traits, and cash flow narratives that matter most to you so you can focus on the highest conviction ideas for your watchlist.

Take Control of Your Investment Journey

If AbbVie or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Beyond These Picks?

Fresh ideas move first, and laggards get caught watching from the sidelines while momentum builds, prices start flying, or quality drops under the radar for now. Consider taking a closer look at:

• Potential early breakouts by scanning curated 18 high quality undiscovered gems that combine quality fundamentals with stories most investors are not watching yet.
• Ways to strengthen your defense as markets swing by reviewing a hand picked list of solid balance sheet and fundamentals (48 results) that can help keep your portfolio grounded when conditions change fast.
• Opportunities to participate in the AI build out from a different angle by checking 49 AI infrastructure stocks powering the hardware, networks, and data centers behind the trend itself.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.